← Back to all signals
RESEARCH PAPER ANALYSIS

Linking executive dysfunction to gait initiation deficits in Parkinson's disease with freezing of gait.

This clinical study shows that impaired inhibition and slowed cognitive flexibility are associated with prolonged anticipatory postural adjustment (APA) duration during gait initiation in Parkinson's patients with freezing of gait, identifying APA duration as a potential biomechanical marker.

PMID41950606
JournalParkinsonism & related disorders
Publication Date2026-04-05
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This clinical study shows that impaired inhibition and slowed cognitive flexibility are associated with prolonged anticipatory postural adjustment (APA) duration during gait initiation in Parkinson's patients with freezing of gait, identifying APA duration as a potential biomechanical marker.

WHY IT MATTERS

Research significance

While not revealing molecular targets, the work highlights a measurable biomechanical biomarker (APA duration) and supports therapeutic strategies aimed at improving postural preparation and executive control (e.g., targeted rehabilitation or neuromodulation) to reduce freezing episodes.

ABSTRACT

Source abstract

INTRODUCTION: Freezing of gait (FoG) is a disabling symptom of Parkinson's disease (PD) that often emerges during gait initiation and is linked to executive dysfunction. We investigated whether cognitive inhibition and processing speed are associated with gait initiation deficits in people with PD with and without FoG. METHODS: Seventy-nine individuals with PD (50 PD + FoG, 29 PD-FoG) and 37 healthy older adults were evaluated. Executive functions were assessed using the Victoria Stroop test and the Trail Making Test, with scores converted to age- and education-adjusted z-scores. Gait initiation was elicited during a cognitive-motor conflict stepping task. Anticipatory postural adjustments (APA) delay, APA duration, APA amplitude, and normalized step amplitude were extracted. Group differences were assessed using Mann-Whitney tests; associations between cognitive and biomechanical variables were examined using Spearman's rank correlation. RESULTS: PD + FoG showed poorer executive performance than PD-FoG on Stroop-III and TMT-B, while the pooled PD group performed worse than healthy controls on all Stroop and TMT measures. Longer APA duration correlated with poorer TMT-B and Stroop-III performance in PD + FoG. Larger amplitudes of mediolateral APA correlate with lower values in nFoGq in PD + FoG. In healthy controls, longer APA delay was associated with poorer TMT-B performance. DISCUSSION: Executive dysfunction-particularly impaired inhibition and slowed cognitive flexibility-is selectively related to prolonged APA duration during gait initiation, especially in PD + FoG. These findings support a model in which FoG arises from the interaction between vulnerable postural preparation and limited executive control, highlighting APA duration as a potential biomechanical marker and therapeutic target.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic